Table 2.
Immunologic marker levels in comparative groups: surviving vs. non-surviving, ARDS vs. non-ARDS
| Non-Surviving Patients [total n = 16] (CI) |
Surviving Patients [total n = 14] (CI) |
P value | Non-ARDS Patients [total n = 13] (CI) |
ARDS Patients [total n = 17] (CI) |
P value | |
|---|---|---|---|---|---|---|
| HMGB-1 (ng/mL)a | 11.76 [13] (-5.65-60) | 6.78 [12] (4.5-17.66) | .44 | 10.11 [11] (4.64-18.97) | 11.11 [14] (-4.83-55.51) | .64 |
| RAGE (MFI)a | 88.88 [15] (55.9-150.8) | 116.7 [14] (51.9-456.2) | .21 | 98.01 [12] (6.68-492.31) | 90.63 [17] (75.55-173.27) | .94 |
| sRAGE (pg/mL)a | 3236 [15] (2312-3673) | 1037 [13] (912.8-2769) | .058 | 1829.75 [13] (1079-2629) | 3296 [15] (2168-3793) | .058 |
HMGB-1, high mobility group box -1, RAGE, receptor for advanced glycation end products; sRAGE, soluble RAGE; MFI, mean fluorescence intensity
[n] Expresses the numeral of results analyzed, from the total number
aData is expressed as median (CI)